Author(s): Benaboud S, Pruvost A, Coffie PA, Ekouvi DK, Urien S, , Benaboud S, Pruvost A, Coffie PA, Ekouvi DK, Urien S,
Abstract Share this page
Abstract The aim was to evaluate emtricitabine (FTC) and tenofovir (TFV) neonatal ingestion through breast milk. Median TFV and FTC breast milk doses represented 0.03\% and 2\%, respectively, of the proposed oral infant doses. Neonatal simulated plasma concentrations were extremely low for TFV but between the half-maximal inhibitory concentration and the adult minimal expected concentration for FTC. The rare children who will acquire HIV despite TDF-FTC therapy will need to be monitored for viral resistance acquisition.
This article was published in Antimicrob Agents Chemother
and referenced in Journal of AIDS & Clinical Research